| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02231164 Details | 2017-03-21 Interventional | 3 | 12 | Docetaxel Nintedanib Carcinoma, Non-… | - The sponsor cancelled this trial prematurely. Thus, enrollment for 1199.128 was significantly less than what was planned (800 planned vs. 12 entered). Therefore, the objectives of this study could not be fully assessed. | |||
| NCT01845025 2012-004854-27 Details | 2017-03-21 Interventional | 4 | 827 | Fluticasone Formoterol Fuma… Xhance Asthma Persistent Asth… | Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was
a commercial reason and not due to any change in benefit-risk. - | |||
| NCT00907166 Details | 2017-03-21 Interventional | 1/2 | 6 | Gemcitabine Carcinoma Pancreatic Neop… Cancer Pancreatic Canc… Pancreatic Carc… | Suspended trial was not restarted. - | |||
| NCT00745823 Details | 2017-03-21 Interventional | 3 | 775 | Emtricitabine, … Raltegravir Pot… HIV | Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg
once daily versus raltegravir 400 mg twice daily The study was terminated before the 96-week efficacy analysis. Adverse event data were collected for the entire treatment period up to a maximum of Week 108, which defines the Overall Study period. | |||
| NCT00496366 Details | 2017-03-21 Interventional | 2 | 11 | Capecitabine Lapatinib Breast Neoplasm… Advanced Breast… Breast Cancer HER2/Neu-positi… Metastatic Brea… | - - | |||
| NCT00464763 Details | 2017-03-21 Interventional | 3 | 0 | Dexmedetomidine Delirium | The incidence of post-operative delirium observed from interim blinded data in DEX-06-09 was
significantly lower than the current literature in this population. - | |||
| NCT00443729 Details | 2017-03-21 Interventional | 3 | 355 | Lopinavir Raltegravir Pot… Ritonavir HIV Infections HIV Infection | Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus
lopinavir (+) ritonavir Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™. | |||
| NCT00443703 Details | 2017-03-21 Interventional | 3 | 352 | Lopinavir Raltegravir Pot… Ritonavir HIV Infections HIV Infection | primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus
lopinavir (+) ritonavir The reason for early termination: Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™. | |||
| NCT02670317 2015-005273-20 Details | 2017-03-20 Interventional | 2 | 1 | Cyclophosphamid… Doxorubicin Ibrutinib Obinutuzumab Prednisone Vincristine Lymphoma Lymphoma, B-Cel… | GA101-CHOP not advantage from rituximab-CHOP - | |||
| NCT01207765 Details | 2017-03-20 Interventional | 2 | 8 | Antibodies, Mon… Multiple Myelom… Neoplasms, Plas… | changes in practice Study ended at end of stage 1 | |||
| NCT02676310 Details | 2017-03-17 Interventional | 1 | 53 | Bimatoprost Alopecia Alopecia Areata Alopecia, Andro… Baldness | - - | |||
| NCT01504659 Details | 2017-03-16 Interventional | 2/3 | 5 | Ketamine Bipolar Disorde… | Administrative issues - | |||
| NCT01145326 Details | 2017-03-16 Interventional | 2/3 | 0 | Lidocaine Pain Perception Phlebotomy | The device is undergoing further study in China, per FDA requirements. - | |||
| NCT01943188 Details | 2017-03-15 Interventional | 1 | 2 | Cyclophosphamid… Carcinoma Carcinoma, Rena… Clear Cell Rena… Recurrent Renal… Stage IV Renal … | - - | |||
| NCT01155791 Details | 2017-03-15 Interventional | 1 | 2 | Docetaxel Prednisone Neoplasm Metast… Prostatic Neopl… Urologic Neopla… Prostate Cancer Prostate Cancer… | - - | |||
| NCT01089595 Details | 2017-03-15 Interventional | 2 | 5 | Imatinib Mesyla… Nilotinib Neoplasm Metast… GIST Metastatic Dise… | Novartis is ending their research program for Nilotinib in GIST. Trial ended early due to industry support of provision of nilotinib was discontinued. | |||
| NCT00571194 Details | 2017-03-15 Interventional | 1 | 7 | Pravastatin Kidney Failure,… End Stage Renal… | - - | |||
| NCT00263211 Details | 2017-03-15 Interventional | 2 | 48 | Aspirin Clopidogrel Breast Neoplasm… | Stopped due to low percentage of patients with detectable CTCs at baseline. Inclusion of patients with no or few CTC's limited ability to distinguish anti-platelet therapeutic effect. Early termination because of low probability of reaching statistical significance for primary outcome | |||
| NCT01357655 2011-000083-10 Details | 2017-03-14 Interventional | 2 | 70 | Dasatinib Leukemia | No participants enrolled in this trial could receive the SMO antagonist as a recommended phase
2 dose was not determined by a different, concurrently-run trial. No recommended phase 2 dose of the SMO antagonist was determined (in a separate trial). It was decided to discontinue enrollment and end this trial early. The decision was not made due to any new safety signals for dasatinib or the SMO antagonist. | |||
| NCT00692003 2007-003557-91 Details | 2017-03-14 Interventional | 3 | 21 | Zonisamide Seizures Epilepsy | Sponsor's decision This study was terminated early at the Sponsor's discretion. When this study was discontinued, only 6 subjects had been treated. Data from the 5 subjects treated with zonisamide were insufficient to draw firm conclusions regarding efficacy. |